World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
76
Citations
59733
World Ranking
18593
National Ranking
9261

Overview

Steven J. O'Day is affiliated with St. John's University in the United States and has a research focus primarily in the field of Medicine, with significant contributions to Oncology, Immunology, and Pulmonary and Respiratory Medicine. Their work spans molecular biology and cancer research, highlighting interdisciplinary expertise.

The scientist has published extensively on subjects related to cancer immunotherapy and biomarkers, CAR-T cell therapy, immunotherapy and immune responses, monoclonal and polyclonal antibodies, melanoma and MAPK pathways, colorectal cancer treatments, and cancer genomics and diagnostics.

Among recent publications are:

  • Lung epithelial and endothelial damage, loss of tissue repair, inhibition of fibrinolysis, and cellular senescence in fatal COVID-19 (2021, Science Translational Medicine)
  • Prevalence of class I-III BRAF mutations among 114,662 cancer patients in a large genomic database (2020, Experimental Biology and Medicine)
  • The Society for Immunotherapy of Cancer perspective on regulation of interleukin-6 signaling in COVID-19-related systemic inflammatory response (2020, Journal for ImmunoTherapy of Cancer)
  • Botensilimab plus balstilimab in relapsed/refractory microsatellite stable metastatic colorectal cancer: a phase 1 trial (2024, Nature Medicine)
  • Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma (2020, JAMA Oncology)

Frequent co-authors collaborating with Steven J. O'Day include:

  • Joseph E. Grossman
  • Andrea J. Bullock
  • Michael S. Gordon
  • Anthony B. El-Khoueiry
  • Dhan Chand

Publication venues where this scientist frequently contributes are:

  • Journal of Clinical Oncology
  • Annals of Oncology
  • Regular and Young Investigator Award Abstracts
  • Cancer Research
  • Journal for ImmunoTherapy of Cancer

Their research emphasizes cancer immunotherapy techniques, biomarker discovery, and the development of targeted therapies for oncology patients. The integration of immune response mechanisms with clinical oncology forms a foundational aspect of their scientific inquiries.

Best Publications

  • Improved Survival with Ipilimumab in Patients with Metastatic Melanoma.

    F. Stephen Hodi;Steven J. O'Day;David F. McDermott;Robert W. Weber

  • Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

    Paul B. Chapman;Axel Hauschild;Caroline Robert;John B. Haanen

  • Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

    Caroline Robert;Luc Thomas;Igor Bondarenko;Steven O'Day

  • Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

    Jedd D. Wolchok;Axel Hoos;Steven O'Day;Jeffrey S. Weber

  • Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

    Antoni Ribas;Igor Puzanov;Reinhard Dummer;Dirk Schadendorf

  • Relationship Between Cancer Patients' Predictions of Prognosis and Their Treatment Preferences

    Jane Weeks;E. Francis Cook;Steven J. O'Day;Lynn M. Peterson

  • Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

    Jedd D Wolchok;Bart Neyns;Gerald Linette;Sylvie Negrier

  • Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

    Grant A McArthur;Paul B Chapman;Caroline Robert;James Larkin

  • Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

    Gerald S Falchook;Georgina V Long;Georgina V Long;Razelle Kurzrock;Kevin B Kim

  • Clinical Cancer Advances 2013: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology

    Jyoti D. Patel;Lada Krilov;Sylvia Adams;Carol Aghajanian

  • Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

    Axel Hauschild;Sanjiv S. Agarwala;Uwe Trefzer;David Hogg

  • A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

    Jeffrey Weber;John A. Thompson;Omid Hamid;David Minor

  • Imatinib for Melanomas Harboring Mutationally Activated or Amplified KIT Arising on Mucosal, Acral, and Chronically Sun-Damaged Skin

    F. Stephen Hodi;Christopher L. Corless;Anita Giobbie-Hurder;Jonathan A. Fletcher

  • Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study

    S. J. O'Day;M. Maio;V. Chiarion-Sileni;T. F. Gajewski

  • Phase I/II study of ipilimumab for patients with metastatic melanoma

    Jeffrey S. Weber;Steven O’Day;Walter Urba;John Powderly

  • Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.

    Steven J. O'Day;Omid Hamid;Walter J. Urba

  • A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma.

    Evan M. Hersh;Steven J. O’Day;John Powderly;Khuda D. Khan

  • Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

    Jedd D. Wolchok;F. Stephen Hodi;Jeffrey S. Weber;James P. Allison

  • Final Results of Phase III SYMMETRY Study: Randomized, Double-Blind Trial of Elesclomol Plus Paclitaxel Versus Paclitaxel Alone As Treatment for Chemotherapy-Naive Patients With Advanced Melanoma

    Steven J. O'Day;Alexander M.M. Eggermont;Vanna Chiarion-Sileni;Richard Kefford

  • Prolonged survival after complete resection of disseminated melanoma and active immunotherapy with a therapeutic cancer vaccine

    Eddy C. Hsueh;Richard Essner;Leland J. Foshag;David W. Ollila

Frequent Co-Authors

Rene Gonzalez
Rene Gonzalez University of Colorado Anschutz Medical Campus
Jedd D. Wolchok
Jedd D. Wolchok Cornell University
Dave S.B. Hoon
Dave S.B. Hoon St. John's University
Omid Hamid
Omid Hamid Cedars-Sinai Medical Center
Donald L. Morton
Donald L. Morton Saint John's Health Center
Jeffrey S. Weber
Jeffrey S. Weber New York University
He-Jing Wang
He-Jing Wang University of California, Los Angeles
Walter J. Urba
Walter J. Urba Providence Portland Medical Center
Georgina V. Long
Georgina V. Long University of Sydney
Caroline Robert
Caroline Robert University of Paris-Saclay

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a future in medicine, there are several related online degree options and career pathways to explore. For those interested in patient care, online adn programs can be a flexible entry point, allowing you to become a Registered Nurse (RN) in a shorter timeframe.

Not all healthcare careers require direct patient interaction. For example, accredited medical billing and coding schools with financial aid offer programs designed to launch your career on the administrative side of healthcare, ensuring vital operations behind the scenes.

If you already hold a non-nursing bachelor’s degree and want to fast-track into nursing, some institutions provide absn programs that don't require teas or other entrance testing, making it easier to transition to the field.

For those interested in leadership or management roles, a health care administration degree online can prepare you for jobs overseeing healthcare facilities, departments, or systems—all with the convenience of online study.

Best Scientists Citing Steven J. O'Day

Trending Scientists

Recently Published Articles